初治HIV-1感染成人接受利托那韦增强达芦那韦联合拉替拉韦或替诺福韦-恩曲他滨后血液端粒长度变化
NEAT001/ANRS143随机试验显示,在805例初治HIV-1感染成人中,利托那韦增强达芦那韦联合拉替拉韦相比替诺福韦二吡呋酯/恩曲他滨非劣效。对201例随机选取者检测全血端粒长度,第96周时替诺福韦二吡呋酯/恩曲他滨组端粒长度增益显著高于拉替拉韦组,校正基线端粒长度后组间平均变化差为0.031(P=.009)。
要点
- 第96周时替诺福韦二吡呋酯/恩曲他滨组端粒长度增益显著高于拉替拉韦组(差值0.031,P=.009)。
- 该差异经年龄、性别、HIV感染已知病程、CD4、CD8、CD4/CD8比值、病毒载量等校正后无显著混杂。
- 结果提示含替诺福韦方案可能带来更好的HIV相关免疫衰老初始恢复。
核心结论
- 初治HIV感染成人接受利托那韦增强达芦那韦联合替诺福韦二吡呋酯/恩曲他滨者,血液端粒长度增益显著高于接受利托那韦增强达芦那韦联合拉替拉韦者,提示前者可能有更好的HIV相关免疫衰老初始恢复。
研究设计与样本
- NEAT001/ANRS143随机试验,在805例初治HIV感染成人中比较利托那韦增强达芦那韦联合拉替拉韦与替诺福韦二吡呋酯/恩曲他滨。
- 从805例中随机选取201例(拉替拉韦组104例,替诺福韦二吡呋酯/恩曲他滨组97例),用定量聚合酶链反应检测全血端粒长度。
- 采用多变量估计性和预测性线性回归分析。
主要发现
- 第96周时,替诺福韦二吡呋酯/恩曲他滨组端粒长度增益显著高于拉替拉韦组。
- 校正基线端粒长度后,两组从基线至第96周端粒长度平均变化差值(替诺福韦二吡呋酯/恩曲他滨组减拉替拉韦组)为0.031(P=.009)。
- 该差异不受年龄、性别、HIV感染已知病程、CD4(基线/最低值)、CD8细胞、CD4/CD8比值、HIV病毒载量(基线/第96周)、烟草和酒精消费、他汀类药物或丙型肝炎的显著混杂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tenofovir is a potent inhibitor of human telomerase. The clinical relevance of this inhibition is unknown. METHODS: NEAT001/ANRS143 is a randomized trial that showed noninferiority over 96 weeks of ritonavir-boosted darunavir plus raltegravir versus tenofovir disoproxil fumarate/emtricitabine in 805 antiretroviral antiretrovrial-naive HIV-infected adults. We compared changes in whole-blood telomere length measured with quantitative polymerase chain reaction in 201 randomly selected participants (104 raltegravir and 97 tenofovir disoproxil fumarate/emtricitabine). We performed multivariable estimative and predictive linear regression. RESULTS: At week 96, participants receiving tenofovir disoproxil fumarate/emtricitabine had a statistically significant higher gain in telomere length than participants receiving raltegravir. Difference in mean telomere length change between groups (tenofovir disoproxil fumarate/emtricitabine minus raltegravir) from baseline to week 96 adjusted by baseline telomere length was 0.031 (P = .009). This difference was not significantly confounded by age, gender, known duration of HIV infection, CD4 (baseline/nadir), CD8 cells, CD4/CD8 ratio, HIV viral load (baseline/week 96), tobacco and alcohol consumption, statins, or hepatitis C. CONCLUSION: Antiretroviral-naive HIV-infected adults receiving ritonavir-boosted darunavir and tenofovir disoproxil fumarate/emtricitabine had a significant higher gain in blood telomere length than those receiving ritonavir-boosted darunavir and raltegravir, suggesting a better initial recovery from HIV-associated immunosenescence.
引用
- Stella-Ascariz N, Montejano R, Rodriguez-Centeno J, et al. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1. J Infect Dis. 2018. PMID: 29982509. doi:10.1093/infdis/jiy399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。